epiClinicalA fictional CRO

epiClinical is fictional. It is a portfolio demonstration by Adam Daniels. Its studies, sponsors, sites and enrolment figures are synthetic. The evidence behind its assumptions is real, and every number says how far it can be trusted.

EPI-301, Phase III. Recruiting

Non-small cell lung cancer, second line

NWT-4471 with docetaxel against docetaxel alone in previously treated non-small cell lung cancer. Sponsor: Northwind Therapeutics (fictional), Oncology.

Five leading KPIs warn whether recruitment will reach its target, with the screening funnel and the corrective actions that have evidence behind them.

KPIs at a glance

Data to September 30th 2026. Each measure links to its chart below.

Will the plan work?

Feasibility stretch

55% of site capacity

Watch Competing trials: Many, and the eligible pool is small

Sites open against plan

159 of 159 planned

On course The plan spreads each country's sites over its start-up window

First site open to first patient

1.4 months

On course Alert at 2.3 months

Is recruitment on course?

Enrolment against plan

171 of 210 expected

On course Patients randomised against the plan

Site rate against expectation

×0.80 of expected

Watch All sites pooled

Will the plan work?

The plan needs 159 sites, 55% of what its countries can supply, against many, and the eligible pool is small competing trials. That is stretched: a plan that needs most of the available sites, or competes hard for patients, is more likely to under-recruit.

Sites are opening on schedule

Sites openNumber, by month, against the plan spread over each country's start-up window

Show data
Sites open: planned and actual, by month
MonthPlannedActual
Jan 202500
Apr 202500
Jul 20252419
Oct 20258185
Jan 2026128131
Apr 2026150149
Jul 2026159159
Oct 2026159159

Sources: epiClinical synthetic sites; start-up windows from the planner parameters (D25)

Each site found its first patient in the expected time

Open sites by countryMonths from activation to first patient; hollow dots have none yet; orange marks a wait longer than nine in ten similar sites, or none randomised despite three or more expected

Show data
Months from activation to first patient, by site
SiteCountryMonths to first patientFlagged
301-US-01, HoustonUnited StatesNone yet, 12.9 months openNo
301-US-02, San DiegoUnited StatesNone yet, 16.9 months openNo
301-US-03, CharlotteUnited States0.1No
301-US-04, ChicagoUnited StatesNone yet, 16.0 months openNo
301-US-05, Los AngelesUnited StatesNone yet, 15.4 months openNo
301-US-06, SeattleUnited States6.0No
301-US-07, PhiladelphiaUnited States15.2No
301-US-08, NashvilleUnited States5.0No
301-US-09, AtlantaUnited States10.0No
301-US-10, BostonUnited StatesNone yet, 16.9 months openNo
301-US-11, Salt Lake CityUnited StatesNone yet, 13.3 months openNo
301-US-12, ClevelandUnited StatesNone yet, 13.6 months openNo
301-US-13, DenverUnited States1.5No
301-US-14, PittsburghUnited StatesNone yet, 13.0 months openNo
301-US-15, New YorkUnited StatesNone yet, 14.0 months openNo
301-US-16, DallasUnited StatesNone yet, 13.2 months openNo
301-US-17, MiamiUnited StatesNone yet, 15.7 months openNo
301-US-18, BaltimoreUnited StatesNone yet, 14.6 months openNo
301-US-19, PhoenixUnited StatesNone yet, 11.6 months openNo
301-US-20, MinneapolisUnited States1.0No
301-US-21, HoustonUnited States0.6No
301-US-22, San DiegoUnited StatesNone yet, 13.8 months openNo
301-US-23, CharlotteUnited States2.1No
301-US-24, ChicagoUnited StatesNone yet, 15.4 months openNo
301-US-25, Los AngelesUnited States4.4No
301-US-26, SeattleUnited States6.3No
301-US-27, PhiladelphiaUnited StatesNone yet, 15.0 months openNo
301-US-28, NashvilleUnited States8.5No
301-US-29, AtlantaUnited States1.9No
301-US-30, BostonUnited States3.5No
301-US-31, Salt Lake CityUnited StatesNone yet, 11.6 months openNo
301-US-32, ClevelandUnited StatesNone yet, 15.9 months openNo
301-US-33, DenverUnited StatesNone yet, 11.4 months openNo
301-US-34, PittsburghUnited States7.7No
301-US-35, New YorkUnited States11.1No
301-US-36, DallasUnited StatesNone yet, 16.6 months openNo
301-US-37, MiamiUnited StatesNone yet, 12.6 months openNo
301-US-38, BaltimoreUnited StatesNone yet, 13.5 months openNo
301-US-39, PhoenixUnited StatesNone yet, 12.9 months openNo
301-US-40, MinneapolisUnited StatesNone yet, 13.8 months openNo
301-US-41, HoustonUnited States7.7No
301-US-42, San DiegoUnited StatesNone yet, 11.5 months openNo
301-US-43, CharlotteUnited StatesNone yet, 11.5 months openNo
301-US-44, ChicagoUnited States11.5No
301-US-45, Los AngelesUnited States6.7No
301-US-46, SeattleUnited States11.1No
301-US-47, PhiladelphiaUnited States0.1No
301-US-48, NashvilleUnited States2.9No
301-US-49, AtlantaUnited States6.8No
301-US-50, BostonUnited StatesNone yet, 13.5 months openNo
301-UK-01, CardiffUnited Kingdom3.7No
301-UK-02, NewcastleUnited Kingdom7.9No
301-UK-03, GlasgowUnited KingdomNone yet, 11.7 months openNo
301-UK-04, BirminghamUnited Kingdom11.0No
301-UK-05, LeedsUnited KingdomNone yet, 12.9 months openNo
301-UK-06, SouthamptonUnited Kingdom11.3No
301-UK-07, OxfordUnited Kingdom8.2No
301-UK-08, CambridgeUnited Kingdom1.1No
301-UK-09, LiverpoolUnited KingdomNone yet, 14.7 months openNo
301-UK-10, NottinghamUnited Kingdom2.0No
301-UK-11, SheffieldUnited Kingdom3.2No
301-UK-12, EdinburghUnited Kingdom4.8No
301-UK-13, BristolUnited KingdomNone yet, 13.6 months openNo
301-UK-14, ManchesterUnited Kingdom6.4No
301-UK-15, LondonUnited Kingdom2.5No
301-UK-16, CardiffUnited Kingdom6.2No
301-UK-17, NewcastleUnited KingdomNone yet, 14.0 months openNo
301-UK-18, GlasgowUnited Kingdom0.7No
301-UK-19, BirminghamUnited KingdomNone yet, 11.6 months openNo
301-UK-20, LeedsUnited Kingdom2.7No
301-UK-21, SouthamptonUnited Kingdom5.9No
301-UK-22, OxfordUnited Kingdom1.8No
301-UK-23, CambridgeUnited KingdomNone yet, 12.2 months openNo
301-UK-24, LiverpoolUnited Kingdom3.5No
301-UK-25, NottinghamUnited Kingdom3.8No
301-ES-01, ZaragozaSpain2.8No
301-ES-02, MadridSpain2.2No
301-ES-03, SalamancaSpain0.1No
301-ES-04, ValenciaSpain4.3No
301-ES-05, CórdobaSpain1.9No
301-ES-06, OviedoSpainNone yet, 12.0 months openNo
301-ES-07, GranadaSpainNone yet, 12.8 months openNo
301-ES-08, SevilleSpainNone yet, 11.6 months openNo
301-ES-09, PamplonaSpain0.7No
301-ES-10, MurciaSpainNone yet, 12.8 months openNo
301-ES-11, Santiago de CompostelaSpain5.9No
301-ES-12, MálagaSpain0.6No
301-ES-13, BilbaoSpainNone yet, 8.6 months openNo
301-ES-14, BarcelonaSpain4.3No
301-ES-15, AlicanteSpain0.5No
301-ES-16, ZaragozaSpain6.1No
301-ES-17, MadridSpainNone yet, 12.4 months openNo
301-ES-18, SalamancaSpain4.4No
301-ES-19, ValenciaSpainNone yet, 10.9 months openNo
301-ES-20, CórdobaSpainNone yet, 9.8 months openNo
301-ES-21, OviedoSpain0.0No
301-ES-22, GranadaSpainNone yet, 12.0 months openNo
301-ES-23, SevilleSpain7.3No
301-ES-24, PamplonaSpain7.8No
301-ES-25, MurciaSpain1.0No
301-ES-26, Santiago de CompostelaSpain5.0No
301-ES-27, MálagaSpain6.0No
301-ES-28, BilbaoSpain1.0No
301-ES-29, BarcelonaSpain4.5No
301-ES-30, AlicanteSpain3.3No
301-ES-31, ZaragozaSpain0.6No
301-ES-32, MadridSpain12.9No
301-ES-33, SalamancaSpain4.7No
301-ES-34, ValenciaSpainNone yet, 7.5 months openNo
301-ES-35, CórdobaSpainNone yet, 7.7 months openNo
301-PL-01, WarsawPolandNone yet, 8.1 months openNo
301-PL-02, RzeszówPolandNone yet, 8.2 months openNo
301-PL-03, OlsztynPoland0.7No
301-PL-04, BydgoszczPoland4.4No
301-PL-05, ZamośćPolandNone yet, 6.8 months openNo
301-PL-06, LublinPoland5.4No
301-PL-07, SzczecinPolandNone yet, 7.4 months openNo
301-PL-08, KatowicePoland4.7No
301-PL-09, KrakówPolandNone yet, 8.0 months openNo
301-PL-10, GdańskPolandNone yet, 4.5 months openNo
301-PL-11, BiałystokPoland4.4No
301-PL-12, WrocławPolandNone yet, 6.4 months openNo
301-PL-13, ŁódźPolandNone yet, 4.4 months openNo
301-PL-14, PoznańPoland8.0No
301-PL-15, WarsawPoland2.9No
301-PL-16, RzeszówPoland1.0No
301-PL-17, OlsztynPoland3.4No
301-PL-18, BydgoszczPolandNone yet, 6.4 months openNo
301-PL-19, ZamośćPolandNone yet, 3.9 months openNo
301-PL-20, LublinPolandNone yet, 7.1 months openNo
301-PL-21, SzczecinPolandNone yet, 4.8 months openNo
301-PL-22, KatowicePoland7.0No
301-PL-23, KrakówPolandNone yet, 5.6 months openNo
301-PL-24, GdańskPolandNone yet, 6.9 months openNo
301-PL-25, BiałystokPolandNone yet, 7.8 months openNo
301-TR-01, AnkaraTurkey11.7No
301-TR-02, AntakyaTurkeyNone yet, 11.3 months openNo
301-TR-03, DiyarbakırTurkeyNone yet, 11.8 months openNo
301-TR-04, BursaTurkey2.1No
301-TR-05, MalatyaTurkeyNone yet, 12.1 months openNo
301-TR-06, AdanaTurkeyNone yet, 14.1 months openNo
301-TR-07, İzmirTurkey6.5No
301-TR-08, IstanbulTurkey3.8No
301-TR-09, AntalyaTurkey4.7No
301-TR-10, KayseriTurkey0.6No
301-TR-11, GaziantepTurkeyNone yet, 9.1 months openNo
301-TR-12, KonyaTurkey1.3No
301-IN-01, MumbaiIndiaNone yet, 13.3 months openNo
301-IN-02, ChandigarhIndiaNone yet, 11.1 months openNo
301-IN-03, DelhiIndiaNone yet, 11.6 months openNo
301-IN-04, KochiIndiaNone yet, 9.1 months openNo
301-IN-05, JaipurIndia0.0No
301-IN-06, VelloreIndia9.0No
301-IN-07, ChennaiIndia10.3No
301-IN-08, NagpurIndia1.5No
301-IN-09, PuneIndia8.2No
301-IN-10, AhmedabadIndiaNone yet, 13.7 months openNo
301-IN-11, HyderabadIndia2.5No
301-IN-12, LucknowIndia14.2No

Source: epiClinical synthetic sites. A slow site can wait months for its first patient by design, so each is judged against its own expected rate. At study level, a first patient more than about 70 days after the first site opened predicted slow accrual (MD Anderson, 4,269 trials). That alert, 2.3 months, drives the scorecard. It is a cut-off from historical data, not a standard.

Is recruitment on course?

Recruitment is keeping pace

Patients randomisedCumulative, against the count the plan expects from each country's rate and opening window

Show data
Patients randomised: planned and actual, by month
MonthPlannedActual
Jan 202500
Apr 202500
Jul 202521
Oct 20251712
Jan 20265145
Apr 20269880
Jul 2026153124
Oct 2026210171

Sources: epiClinical synthetic sites; plan from the planner. Studies under 60% of target at the planned end rarely recovered in NCI data (review note 02).

Which sites are behind their expectation?

Patients randomised as a share of those expectedEach dot a site, against the patients it was expected to recruit since it opened

Limits
Show data
Each site: patients expected to date, patients randomised and how far it is from its expectation
SiteCountryExpectedRandomisedObserved ÷ expectedJudgement
301-US-01, HoustonUnited States0.50×0Within normal variation
301-US-02, San DiegoUnited States1.60×0Within normal variation
301-US-03, CharlotteUnited States0.91×1.118Within normal variation
301-US-04, ChicagoUnited States1.10×0Within normal variation
301-US-05, Los AngelesUnited States1.40×0Within normal variation
301-US-06, SeattleUnited States1.33×2.364Within normal variation
301-US-07, PhiladelphiaUnited States1.11×0.897Within normal variation
301-US-08, NashvilleUnited States0.81×1.225Within normal variation
301-US-09, AtlantaUnited States1.92×1.054Within normal variation
301-US-10, BostonUnited States1.60×0Within normal variation
301-US-11, Salt Lake CityUnited States1.10×0Within normal variation
301-US-12, ClevelandUnited States1.30×0Within normal variation
301-US-13, DenverUnited States1.72×1.211Within normal variation
301-US-14, PittsburghUnited States1.00×0Within normal variation
301-US-15, New YorkUnited States1.20×0Within normal variation
301-US-16, DallasUnited States1.20×0Within normal variation
301-US-17, MiamiUnited States1.50×0Within normal variation
301-US-18, BaltimoreUnited States1.20×0Within normal variation
301-US-19, PhoenixUnited States0.50×0Within normal variation
301-US-20, MinneapolisUnited States1.02×1.943Within normal variation
301-US-21, HoustonUnited States0.63×4.678Within normal variation
301-US-22, San DiegoUnited States1.60×0Within normal variation
301-US-23, CharlotteUnited States1.01×0.969Within normal variation
301-US-24, ChicagoUnited States1.50×0Within normal variation
301-US-25, Los AngelesUnited States1.54×2.628Within normal variation
301-US-26, SeattleUnited States1.12×1.904Within normal variation
301-US-27, PhiladelphiaUnited States0.70×0Within normal variation
301-US-28, NashvilleUnited States0.81×1.19Within normal variation
301-US-29, AtlantaUnited States0.81×1.244Within normal variation
301-US-30, BostonUnited States0.91×1.059Within normal variation
301-US-31, Salt Lake CityUnited States0.80×0Within normal variation
301-US-32, ClevelandUnited States1.30×0Within normal variation
301-US-33, DenverUnited States1.00×0Within normal variation
301-US-34, PittsburghUnited States1.31×0.757Within normal variation
301-US-35, New YorkUnited States1.11×0.892Within normal variation
301-US-36, DallasUnited States2.70×0Within normal variation
301-US-37, MiamiUnited States1.20×0Within normal variation
301-US-38, BaltimoreUnited States1.30×0Within normal variation
301-US-39, PhoenixUnited States0.90×0Within normal variation
301-US-40, MinneapolisUnited States1.00×0Within normal variation
301-US-41, HoustonUnited States1.22×1.612Within normal variation
301-US-42, San DiegoUnited States0.80×0Within normal variation
301-US-43, CharlotteUnited States1.30×0Within normal variation
301-US-44, ChicagoUnited States1.11×0.887Within normal variation
301-US-45, Los AngelesUnited States1.63×1.886Within normal variation
301-US-46, SeattleUnited States1.31×0.782Within normal variation
301-US-47, PhiladelphiaUnited States0.83×3.643Within normal variation
301-US-48, NashvilleUnited States0.91×1.15Within normal variation
301-US-49, AtlantaUnited States1.61×0.616Within normal variation
301-US-50, BostonUnited States1.30×0Within normal variation
301-UK-01, CardiffUnited Kingdom1.31×0.766Within normal variation
301-UK-02, NewcastleUnited Kingdom1.02×2.042Within normal variation
301-UK-03, GlasgowUnited Kingdom1.30×0Within normal variation
301-UK-04, BirminghamUnited Kingdom1.72×1.206Within normal variation
301-UK-05, LeedsUnited Kingdom1.60×0Within normal variation
301-UK-06, SouthamptonUnited Kingdom1.91×0.521Within normal variation
301-UK-07, OxfordUnited Kingdom1.72×1.191Within normal variation
301-UK-08, CambridgeUnited Kingdom1.31×0.753Within normal variation
301-UK-09, LiverpoolUnited Kingdom2.00×0Within normal variation
301-UK-10, NottinghamUnited Kingdom1.24×3.256Within normal variation
301-UK-11, SheffieldUnited Kingdom1.31×0.799Within normal variation
301-UK-12, EdinburghUnited Kingdom1.21×0.827Within normal variation
301-UK-13, BristolUnited Kingdom1.10×0Within normal variation
301-UK-14, ManchesterUnited Kingdom1.53×2.017Within normal variation
301-UK-15, LondonUnited Kingdom2.33×1.333Within normal variation
301-UK-16, CardiffUnited Kingdom1.85×2.849Within normal variation
301-UK-17, NewcastleUnited Kingdom1.10×0Within normal variation
301-UK-18, GlasgowUnited Kingdom1.22×1.669Within normal variation
301-UK-19, BirminghamUnited Kingdom1.70×0Within normal variation
301-UK-20, LeedsUnited Kingdom1.73×1.786Within normal variation
301-UK-21, SouthamptonUnited Kingdom1.83×1.71Within normal variation
301-UK-22, OxfordUnited Kingdom1.65×3.201Within normal variation
301-UK-23, CambridgeUnited Kingdom1.10×0Within normal variation
301-UK-24, LiverpoolUnited Kingdom1.31×0.781Within normal variation
301-UK-25, NottinghamUnited Kingdom1.72×1.184Within normal variation
301-ES-01, ZaragozaSpain1.72×1.193Within normal variation
301-ES-02, MadridSpain1.16×5.456Above the expected range
301-ES-03, SalamancaSpain1.32×1.497Within normal variation
301-ES-04, ValenciaSpain1.91×0.526Within normal variation
301-ES-05, CórdobaSpain0.92×2.145Within normal variation
301-ES-06, OviedoSpain1.60×0Within normal variation
301-ES-07, GranadaSpain1.20×0Within normal variation
301-ES-08, SevilleSpain1.50×0Within normal variation
301-ES-09, PamplonaSpain1.85×2.785Within normal variation
301-ES-10, MurciaSpain1.60×0Within normal variation
301-ES-11, Santiago de CompostelaSpain2.22×0.916Within normal variation
301-ES-12, MálagaSpain1.75×3.029Within normal variation
301-ES-13, BilbaoSpain0.70×0Within normal variation
301-ES-14, BarcelonaSpain1.51×0.673Within normal variation
301-ES-15, AlicanteSpain1.42×1.443Within normal variation
301-ES-16, ZaragozaSpain1.51×0.684Within normal variation
301-ES-17, MadridSpain1.00×0Within normal variation
301-ES-18, SalamancaSpain1.52×1.334Within normal variation
301-ES-19, ValenciaSpain1.00×0Within normal variation
301-ES-20, CórdobaSpain1.20×0Within normal variation
301-ES-21, OviedoSpain2.02×1.015Within normal variation
301-ES-22, GranadaSpain1.10×0Within normal variation
301-ES-23, SevilleSpain1.61×0.617Within normal variation
301-ES-24, PamplonaSpain0.81×1.193Within normal variation
301-ES-25, MurciaSpain1.11×0.89Within normal variation
301-ES-26, Santiago de CompostelaSpain1.52×1.337Within normal variation
301-ES-27, MálagaSpain0.91×1.12Within normal variation
301-ES-28, BilbaoSpain2.36×2.597Within normal variation
301-ES-29, BarcelonaSpain2.31×0.437Within normal variation
301-ES-30, AlicanteSpain1.42×1.47Within normal variation
301-ES-31, ZaragozaSpain1.72×1.212Within normal variation
301-ES-32, MadridSpain1.71×0.592Within normal variation
301-ES-33, SalamancaSpain1.51×0.651Within normal variation
301-ES-34, ValenciaSpain0.90×0Within normal variation
301-ES-35, CórdobaSpain0.50×0Within normal variation
301-PL-01, WarsawPoland1.10×0Within normal variation
301-PL-02, RzeszówPoland1.50×0Within normal variation
301-PL-03, OlsztynPoland1.03×2.933Within normal variation
301-PL-04, BydgoszczPoland0.81×1.237Within normal variation
301-PL-05, ZamośćPoland1.50×0Within normal variation
301-PL-06, LublinPoland0.91×1.13Within normal variation
301-PL-07, SzczecinPoland1.30×0Within normal variation
301-PL-08, KatowicePoland0.92×2.217Within normal variation
301-PL-09, KrakówPoland0.70×0Within normal variation
301-PL-10, GdańskPoland0.40×0Within normal variation
301-PL-11, BiałystokPoland1.82×1.097Within normal variation
301-PL-12, WrocławPoland0.70×0Within normal variation
301-PL-13, ŁódźPoland1.40×0Within normal variation
301-PL-14, PoznańPoland1.81×0.569Within normal variation
301-PL-15, WarsawPoland0.81×1.291Within normal variation
301-PL-16, RzeszówPoland1.01×1.033Within normal variation
301-PL-17, OlsztynPoland1.41×0.719Within normal variation
301-PL-18, BydgoszczPoland0.80×0Within normal variation
301-PL-19, ZamośćPoland0.60×0Within normal variation
301-PL-20, LublinPoland0.80×0Within normal variation
301-PL-21, SzczecinPoland0.40×0Within normal variation
301-PL-22, KatowicePoland0.82×2.392Within normal variation
301-PL-23, KrakówPoland0.70×0Within normal variation
301-PL-24, GdańskPoland1.50×0Within normal variation
301-PL-25, BiałystokPoland1.30×0Within normal variation
301-TR-01, AnkaraTurkey2.51×0.4Within normal variation
301-TR-02, AntakyaTurkey1.10×0Within normal variation
301-TR-03, DiyarbakırTurkey1.10×0Within normal variation
301-TR-04, BursaTurkey2.45×2.089Within normal variation
301-TR-05, MalatyaTurkey1.50×0Within normal variation
301-TR-06, AdanaTurkey1.50×0Within normal variation
301-TR-07, İzmirTurkey1.72×1.166Within normal variation
301-TR-08, IstanbulTurkey1.81×0.555Within normal variation
301-TR-09, AntalyaTurkey1.32×1.498Within normal variation
301-TR-10, KayseriTurkey1.81×0.563Within normal variation
301-TR-11, GaziantepTurkey1.10×0Within normal variation
301-TR-12, KonyaTurkey1.31×0.792Within normal variation
301-IN-01, MumbaiIndia1.40×0Within normal variation
301-IN-02, ChandigarhIndia1.50×0Within normal variation
301-IN-03, DelhiIndia1.60×0Within normal variation
301-IN-04, KochiIndia0.60×0Within normal variation
301-IN-05, JaipurIndia1.71×0.585Within normal variation
301-IN-06, VelloreIndia2.31×0.428Within normal variation
301-IN-07, ChennaiIndia1.61×0.61Within normal variation
301-IN-08, NagpurIndia3.62×0.549Within normal variation
301-IN-09, PuneIndia1.92×1.05Within normal variation
301-IN-10, AhmedabadIndia1.90×0Within normal variation
301-IN-11, HyderabadIndia2.42×0.826Within normal variation
301-IN-12, LucknowIndia1.51×0.654Within normal variation

Source: epiClinical synthetic sites. Allowing for site spread (coefficient of variation 0.9), a site expected to recruit a handful of patients can recruit none and still be within normal variation. Poisson-only limits flag far more sites.

2023 earthquake province is behind: ×0.00 of the patients expected

Sites grouped by country and flagged regionPatients randomised as a share of those expected; the bar is where an ordinary group of that size would land

Show data
Each group: sites, patients randomised against expected, and the range ordinary groups of that size fall in
GroupSitesRandomisedExpectedObserved ÷ expectedOrdinary rangeJudgement
United States503959.3×0.657×0.66 to ×1.389Within normal variation
United Kingdom254237.1×1.131×0.563 to ×1.527Within normal variation
Spain355249.5×1.05×0.617 to ×1.45Within normal variation
Poland251525.8×0.581×0.516 to ×1.592Within normal variation
Turkey121319.1×0.679×0.404 to ×1.783Within normal variation
India121022.3×0.449×0.413 to ×1.773Within normal variation
2023 earthquake province506.4×0×0.125 to ×2.329Below the inner limit
Belarus border region223.1×0.643×0 to ×3.16Within normal variation
Syria border region202.2×0×0 to ×3.332Within normal variation
Ukraine border region626.2×0.321×0.132 to ×2.295Within normal variation

Source: epiClinical synthetic sites

Where patients are lost before randomisation

Benchmarks for each step from referral to randomisation. Screen failure explains where patients are lost; on its own it does not predict whether a study reaches its target.

StepTypical conversionSource
Trial available at the patient's centre (cancer care)44.4% (100% minus 55.6% with no trial available)Unger 2019, JNCI, https://doi.org/10.1093/jnci/djy221
Eligible, among patients with a trial available (cancer care, derived)about 52% ((14.8 + 8.1) / 44.4). Note: the often-quoted 78.5% appears to be 100% minus 21.5%, a misreading because 21.5% is a share of all patientsUnger 2019, JNCI, https://doi.org/10.1093/jnci/djy221
Eligible among screened (primary care trials)median 83% (IQR 40% to 100%)Jones 2009, BMC Family Practice, https://doi.org/10.1186/1471-2296-10-5
Eligible among screened (knee osteoarthritis trials)median 71.9%Koog et al., Archives of Rheumatology, https://archivesofrheumatology.org/full-text/650
Approached among eligible (one oncology trial)91%Lewis 2020, Trials, https://doi.org/10.1186/s13063-020-04559-w
Agreed among those offered a trial (cancer trials, 35 studies)about 55% (55.0% treatment, 55.3% cancer control)Unger 2021, JNCI, https://doi.org/10.1093/jnci/djaa155
Agreed among approached (one oncology trial)40%Lewis 2020, Trials, https://doi.org/10.1186/s13063-020-04559-w
Consented and randomised among eligible (388 NIHR trials)median 72% (IQR 50% to 88%)Jacques 2022, BMJ Open, https://doi.org/10.1136/bmjopen-2021-059230
Enrolled among eligible (primary care trials)median 74% (IQR 49% to 92%)Jones 2009, BMC Family Practice, https://doi.org/10.1186/1471-2296-10-5
Enrolled among all cancer patients (end to end)8.1% (15.9% academic, 7% community centres)Unger 2019, JNCI, https://doi.org/10.1093/jnci/djy221
Screen failure after consent (oncology, one LMIC centre, 15 RCTs)51% failed (49% randomised); main causes inclusion criteria not met 54.9%, declined treatment 22.2%Parekh 2022, ecancermedicalscience, https://doi.org/10.3332/ecancer.2022.1476
Screen failure after consent (prodromal Alzheimer's, industry source)76% to 80% in two trials, against a typical 25% to 30% (grade D, not peer-reviewed)Worldwide Clinical Trials 2017 blog, https://www.worldwide.com/blog/2017/10/unique-4-step-approach-limits-high-screen-failure-in-alzheimers-disease-research-part-1/
Retained with valid primary outcome among randomised (388 NIHR trials)median 88% (IQR 80% to 97%)Jacques 2022, BMJ Open, https://doi.org/10.1136/bmjopen-2021-059230
Recruitment rate (388 NIHR trials)median 0.95 participants per centre per month (IQR 0.42 to 2.60)Jacques 2022, BMJ Open, https://doi.org/10.1136/bmjopen-2021-059230
Consent to randomisation intervalno published benchmark found; protocol-specific, label any default Illustrativenone found

What works when a measure goes red

The evidence review's 16 corrective and preventive actions (CAPAs), strongest evidence first. Grade A is strong, D means no quantitative evidence was found.

ActionGradeAnswersEffect
Telephone follow-up of people who did not reply to an invitationAlow enrolment rate; low response to invitation lettersRisk difference +6 percentage points (95% CI 3 to 9), high certainty, clearest where baseline recruitment is low (under about 10% of those invited). Earlier version: RR 1.66 (95% CI 1.03 to 2.46), 2 studies, 1,058 participants.
Open rather than blinded placebo design (design stage only)Apredicted low enrolment at feasibility; high refusal linked to placeboRisk difference +10 percentage points (95% CI 7 to 13), high certainty.
Monetary thank-you for returning follow-up questionnairesBhigh drop-out; missing primary outcome data; low questionnaire returnPostal: RR 1.18 (95% CI 1.09 to 1.28); higher vs lower value RR 1.12 (1.04 to 1.22); electronic, offered on receipt, RR 1.25 (1.14 to 1.38). 2021 update: incentive vs usual follow-up RR 1.20 (1.06 to 1.36), 3 studies, 3,166 participants, low certainty.
Pre-notification before follow-up, with reward or reminderBhigh drop-out; low questionnaire returnMonetary reward with reminder or pre-notification improved retention, moderate certainty; no pooled number extracted. PROMETHEUS SWATs found pre-notification effective; no effect size in the abstract.
Reduce follow-up burden (home self-sampling, no extra diaries)Bhigh drop-out; missed visits; missing primary outcome dataSelf-sampling kits improved retention, moderate certainty (no pooled number extracted). Adding a diary reduced retention: RR 0.97 (95% CI 0.96 to 0.98), 2 studies, 9,906 participants, moderate certainty.
Opt-out contact for potential participantsClow enrolment rate; few patients approachedRR 1.39 (95% CI 1.06 to 1.84), but from a single study of 152 people; not among the high-certainty findings of the 2018 update.
Personalised text messages for follow-upChigh drop-out; low questionnaire returnMixed: PROMETHEUS found personalised texts improved questionnaire response (no effect size in abstract); Cochrane pooled electronic reminders RR 1.01 (95% CI 0.95 to 1.09), 3 studies, 790 participants, low certainty.
Broaden eligibility criteria by protocol amendmentChigh screen failure; low eligible-to-screened ratio; low enrolment rateModelled in advanced NSCLC real-world data (61,094 patients): relaxing restrictive criteria more than doubled the eligible pool on average, with hazard ratio change of about 0.05 and no rise in toxicity-related discontinuation. No prospective evidence of the effect on actual randomisations. Amendments: median direct cost about $141k (phase II) and $535k (phase III), about 3 months added.
Participant payments or reimbursementClow consent among approached; low enrolment rateMixed in two RCTs: smoking-cessation trial consent 21.8% ($0) vs 35.9% ($200) vs 47.1% ($500); ambulation trial no effect (45.4%, 48.1%, 43.0%). No evidence of undue inducement in these low-risk trials.
Add decentralised elementsClow enrolment rate; high drop-out; patients living far from sitesOf 13 studies, 10 or 11 reported better recruitment with decentralised methods, mostly without head-to-head comparison; a 2022 systematic review found insufficient comparable data to say whether decentralised trials recruit or retain better.
Screening-log review to find the leaking funnel stageCany red recruitment KPI; high screen failure; low consent among approachedNo quantitative evidence that logs raise recruitment. In one oncology trial, logs showed 91% of eligible patients approached but 40% agreeing, pointing at the consent conversation; logs were incomplete (47% returned; 28% of enrolled patients missing).
Close or replace non-enrolling sitesDsites with zero enrolment; low site productivity; slow activationNo quantitative evidence on the effect of closing sites. Context only: 11% of activated sites enrol no one and 37% under-enrol (Tufts CSDD 2012 data).
Add sites or countriesDlow enrolment rate; forecast misses last patient in dateNo quantitative evidence on adding sites as a rescue. Diminishing returns follow from activation lag and site variability rather than from a measured effect. Context: median 0.95 participants per centre per month (IQR 0.42 to 2.60) in NIHR trials.
Increase site or investigator paymentsDlow site productivity; low enrolment rateNo quantitative evidence for patient recruitment; a 2005 systematic review found almost no experimental evidence and raised conflict-of-interest concerns. One RCT of paying doctors concerned recruiting doctors as study subjects, not patient recruitment.
Central campaigns, recruitment vendors and referral networksDfew patients identified; no trial available at local centres; low enrolment rateNo quantitative evidence found in peer-reviewed comparative studies within this review. Context: in cancer care, no trial was available at the patient's centre for 55.6% of patients, which referral networks aim to address.
Site re-training and extra site support visitsDlow site productivity; low approach rate; high screen failure from avoidable errorsNo quantitative evidence found; the 2021 Cochrane retention review found only two studies targeting site staff.